Current Edition

chief commercial officer

GlaxoSmithKline vet departs for Vifor, the rumored target of a $7.1B CSL buyout

With a recent pruritus approval in the books and several more potential launches coming in the next year and a half, Switzerland’s Vifor Pharma is …

Continue Reading →
antibodies

GlaxoSmithKline and Vir’s sotrovimab stands up to omicron despite other COVID antibodies falling short

Amid reports that COVID-19 antibody treatments from Regeneron and Eli Lilly lose their effectiveness against the omicron variant, GlaxoSmithKline and Vir Biotechnology said on Tuesday …

Continue Reading →
Cabenuva

GSK’s ViiV looks to future of injectable HIV treatment as long-acting PrEP decision looms

The future of ViiV Healthcare’s HIV business is injectable. By 2026, the majority-GlaxoSmithKline-owned joint venture expects long-acting regimens to generate around £2 billion ($2.65 billion) …

Continue Reading →
GlaxoSmithKline

GlaxoSmithKline to leave landmark global HQ after split-up as consumer health business plots £120M new home

GlaxoSmithKline isn’t just making changes with its U.S. operations. The company is now exploring a new location for its global headquarters amid a historic business …

Continue Reading →
biopharma

GlaxoSmithKline relocates US operations in Philadelphia, North Carolina as COVID-19 cuts its office space needs

Many companies have shifted their way of working amid COVID-19. Adjusting to how work is done these days, GlaxoSmithKline is downsizing its office footprint in …

Continue Reading →
cabotegravir

GlaxoSmithKline’s long-acting HIV drug nabs FDA priority review as a preventative option

GlaxoSmithKline’s long-acting HIV drug cabotegravir is already challenging market leaders as part of an approved treatment regimen. Now, the medicine is a step closer to …

Continue Reading →
AbbVie

CEOs of AbbVie, BMS, Lilly, GSK and more raise concerns about Washington’s intensifying drug-pricing push

As officials in Washington weigh contentious drug-pricing measures, there’s even more evidence that pharma companies are worried about potential reform. In an open letter to …

Continue Reading →